TLDR
- Definium Therapeutics stock surged as much as ~52% on June 22, 2026, after its Phase 3 Emerge trial of DT120 met its primary endpoint for major depressive disorder
- DT120 delivered an 8.1-point placebo-adjusted improvement on the MADRS depression scale at Week 6, with rapid benefit seen as early as Week 1
- The drug showed a clean safety profile — 99% of side effects were mild to moderate, with no new safety signals or increase in suicidality
- Definium holds ~$411.6 million in cash, no near-term funding needs, and DT120 carries FDA Breakthrough Therapy Designation
- Multiple Wall Street firms including Jefferies, RBC Capital, and Canaccord Genuity hold Buy ratings; one analyst set a $44 price target in early June
Definium Therapeutics (DFTX) stock jumped as much as 52% on Monday after the company reported that its Phase 3 Emerge trial of DT120 hit its primary endpoint for major depressive disorder.
Before the open, the stock was already up ~39% to $34.01. By mid-session it had pushed further, trading above $37 — well past its prior 52-week high of $26.25.
The trial enrolled adults with major depressive disorder and tested a single 100 microgram oral dose of DT120, a proprietary tablet formulation of lysergide (LSD). The study met its primary goal with an 8.1-point placebo-adjusted improvement on the Montgomery-Åsberg Depression Rating Scale at Week 6.
That result cleared the statistical threshold with a p-value below 0.0001. Patients also showed benefit as early as Week 1, and the improvement held through Week 12.
Secondary measures backed up the primary data, including Clinical Global Impressions severity scores, which also showed improvement.
On safety, the data looked clean. About 99% of treatment-emergent side effects were mild to moderate, discontinuation rates were comparable to placebo, and there were no new safety signals or increase in suicidality — a key concern for this drug class.
Analyst Backing Was Already in Place
Definium didn’t walk into this readout without support. Jefferies, RBC Capital, Canaccord Genuity, and LifeSci Capital had all reiterated Buy ratings in the weeks leading up to the announcement.
Analyst Francois Brisebois raised his price target to $44 in early June, citing a “de-risked” opportunity for DT120 across both anxiety and depression. The most recent analyst rating on the stock sits at Buy with a $38 price target.
The company also enters this milestone from a position of financial strength. Definium had approximately $411.6 million in cash as of the latest report, with no near-term funding needs. That runway is expected to carry through 2028.
DT120 also holds FDA Breakthrough Therapy Designation, which could smooth the path toward regulatory submission.
What Comes Next
Definium has a second Phase 3 trial underway called Ascend, which is aligned in design with Emerge. The company now has one clean positive readout to support an eventual NDA submission for major depressive disorder.
Peer Compass Pathways (CMPS) also traded higher on the day, suggesting the Emerge results lifted sentiment across the psychedelic therapeutics space.
The broader market was constructive as well, with the Nasdaq gaining 1.9% and the S&P 500 adding 1.1%.
The current market cap for Definium sits at approximately $2.67 billion following the move.
🚨 Our JUNE Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for June, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
